menu

Loading...

Should I Buy EDSA? EDSA 2026 Analysis - Intellectia AI™

Should You Buy Edesa Biotech Inc (EDSA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.200

1 Day change

41.94%

52 Week Range

2.950

Analysis Updated At

2026/02/27

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Edesa Biotech Inc. (EDSA) shows positive news sentiment driven by promising drug trial results, but the company's weak financial performance and lack of significant trading signals suggest it is not an ideal buy for a beginner, long-term investor at this moment.

Technical Analysis

The MACD histogram is positive and expanding, indicating bullish momentum. RSI is neutral at 72.334, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level of R1: 1.607, which could act as a barrier for further upward movement.

Positive Catalysts

Edesa Biotech's drug paridiprubart showed significant reductions in mortality rates in Phase 3 trials, with plans for patent applications and presentations at a major conference. This has driven strong positive sentiment in recent news.

Neutral/Negative Catalysts

The company's financials for Q1 2026 are weak, with net income and EPS showing significant declines. Additionally, there is no strong hedge fund or insider trading activity to support a bullish case.

Financial Performance

In Q1 2026, revenue remained at 0 with no growth YoY. Net income dropped by 100%, and EPS declined by 41.67%, indicating poor financial health.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

1 Analyst Rating

Wall Street analysts forecast EDSA stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.550

Low

5

Averages

5

High

5

Current: 1.550

Low

5

Averages

5

High

5

H.C. Wainwright

Yi Chen

initiated

$5

AI Analysis

2025-06-27

Reason

H.C. Wainwright

Yi Chen

Price Target

$5

AI Analysis

2025-06-27

initiated

Reason

H.C. Wainwright analyst Yi Chen assumed coverage of Edesa Biotech with a Buy rating and $5 price target. Edesa is a clinical stage biopharmaceutical company primarily focused on the development of novel treatments for dermatology and respiratory indications, the analyst tells investors in a research note. The firm says the company's lead drug candidate EB06 has a favorable safety and tolerability profile for treating vitiligo.

Lucid Capital

Dev Prasad

Buy

initiated

$9

2025-05-23

Reason

Lucid Capital

Dev Prasad

Price Target

$9

2025-05-23

initiated

Buy

Reason

Lucid Capital analyst Dev Prasad initiated coverage of Edesa Biotech with a Buy rating and $9 price target. The firm has a positive outlook on the company's lead clinical asset, EB06. EB06 is a first-in-class, fully human monoclonal antibody targeting CXCL10, in development for the treatment of moderate-to-severe non-segmental vitiligo, a chronic autoimmune skin disorder with high unmet medical need, the analyst tells investors in a research note. Lucid says the mechanism of action is well-supported by a strong biological rationale. Lucid views Edesa as an attractive long-term growth opportunity, with a first-in-class asset.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EDSA

Unlock Now

People Also Watch